{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:53Z","timestamp":1791478253067,"version":"4.3.4"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment of acute hepatitis C (AHC) with direct\u2010acting antiviral agents (DAAs) is considered a cornerstone of hepatitis C virus (HCV) elimination strategies, especially in human immunodeficiency virus (HIV)\u2010infected individuals at high risk of onward transmission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Optimal treatment regimens and duration for AHC in HIV\u2010coinfected patients remain to be established. Thus, we aimed to evaluate the efficacy and safety of DAA treatment regimens in the setting of AHC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All HIV\u2010positive patients with a diagnosis of AHC according to the European AIDS Treatment Network (NEAT) consensus attending our clinic after 2014 were included. DAA treatment regimens and duration were based on current recommendations for chronic hepatitis C (CHC) at treatment initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010eight HIV\/AHC patients (median age 42.0 years), mostly men who have sex with men (92%), were started on interferon\u2010free regimens. HCV\u2010genotype (GT) was predominately GT\u20101a (65%). The following DAA regimens were prescribed: ombitasvir\/paritaprevir\/ritonavir\/dasabuvir (42%; 16\/38), glecaprevir\/pibrentasvir (29%; 11\/38), sofosbuvir\/ledipasvir (13%; 5\/38), ombitasvir\/paritaprevir\/ritonavir (5%; 2\/38), grazoprevir\/elbasvir (5%; 2\/38) and sofosbuvir\/velpatasvir (5%; 2\/38). All HIV\/AHC patients achieved sustained virologic response 12 weeks after end of treatment (SVR12) (100%; 38\/38). DAA\u2010related adverse events were rare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Interferon\u2010free DAA regimens (including 34% pan\u2010genotypic regimens) yielded 100% SVR12 in HIV\/AHC individuals if treatment durations similar to CHC are applied.<\/jats:p><\/jats:sec>","DOI":"10.1177\/2050640619835394","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T01:27:50Z","timestamp":1551922070000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["High efficacy of interferon\u2010free therapy for acute hepatitis C in HIV\u2010positive patients"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-8258","authenticated-orcid":false,"given":"David","family":"Chromy","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"},{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2330-0017","authenticated-orcid":false,"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"},{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Bucsics","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"},{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"},{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"},{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Schmidbauer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"},{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"},{"name":"Department of Internal Medicine IV Wilhelminenspital Wiener Krankenanstaltenverbund (KAV) der Stadt Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MC","family":"Aichelburg","sequence":"additional","affiliation":[{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"},{"name":"Division of Immunology, Allergy and Infectious Diseases Department of Dermatology Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"},{"name":"Department of Internal Medicine and Gastroenterology Klinikum Klagenfurt am W\u00f6rthersee Klagenfurt Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna Vienna Austria"},{"name":"Vienna HIV &amp; Liver Study Group Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12848"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ562"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01197.x"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.1.131"},{"key":"e_1_2_10_6_2","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study","volume":"24","author":"Smith C","year":"2010","journal-title":"AIDS"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001020"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix260"},{"key":"e_1_2_10_11_2","first-page":"347","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study","volume":"2","author":"Rockstroh JK","year":"2018","journal-title":"Clin Infect Dis"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0026-5"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28844"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix025"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2017.1280594"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30408-X"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30003-1"},{"key":"e_1_2_10_18_2","first-page":"113A","article-title":"100% SVR with 8 weeks of ledipasvir\/sofosbuvir in HIV-infected men with acute HCV infection: results from the SWIFT-C trial (sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals)","volume":"66","author":"Naggie S","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12917"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1107-z"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12707"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9691-4"},{"key":"e_1_2_10_23_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference","volume":"25","author":"European ATNAHCICP","year":"2011","journal-title":"AIDS"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_2_10_25_2","doi-asserted-by":"crossref","DOI":"10.1007\/s00508-017-1231-x","article-title":"Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV\/HCV coinfected patients","volume":"130","author":"Chromy D","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.018"},{"key":"e_1_2_10_27_2","unstructured":"US Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases.Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Corrected version 2.1 ed.2017. Available at:https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables(accessed 27 February 2019)."},{"key":"e_1_2_10_28_2","unstructured":"Administration USFaD.MedWatch the FDA Safety Information and Adverse Event Reporting Program https:\/\/www.fda.gov\/safety\/medwatch\/howtoreport\/ucm053087.htm(2016 accessed 31 January 2019)."},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv564"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12666"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw567"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0606-0"},{"key":"e_1_2_10_34_2","article-title":"Treatment of non-cirrhotic HCV genotype 4 infected patients with 8 weeks of ledipasvir\/sofosbuvir: an open-label, multicenter clinical trial","author":"Boerekamps A","journal-title":"J Hepatol"},{"key":"e_1_2_10_35_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.dld.2017.11.013","article-title":"Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: a literature review","volume":"50","author":"Lampejo T","year":"2018","journal-title":"Dig Liver Dis"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-015-0912-6"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13315"},{"key":"e_1_2_10_38_2","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(18)30597-X","article-title":"Can HCV be eliminated among HIV-infected MSM in Berlin? Modeling a setting with increasing and high treatment rates","volume":"68","author":"Martin NK","year":"2018","journal-title":"J Hepatol"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619835394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2050640619835394","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619835394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:18:13Z","timestamp":1693732693000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2050640619835394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1177\/2050640619835394"],"URL":"https:\/\/doi.org\/10.1177\/2050640619835394","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}